TheProductLawyers.com reports on a recent postponement of bellwether trials involving Xarelto lawsuits.
During the short period of time that the drug has been on the market, thousands of lawsuits have been filed alleging life-threatening and sometimes fatal side effects.
TheProductLawyers.com reports on a recent delay issued by the FDA for a possible antidote to Xarelto, a blood-thinning drug that has allegedly caused a number of adverse side effects for patients.
In Louisiana, another group in excess of 2,800 federal cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) and given number 2592.
TheProductLawyers.com reports on the recent order given by Judge Eldon Fallon who is overseeing the Xarelto MDL 2592.
TheProductLawyers.com reports on the controversy swirling about Xarelto, a blood-thinning drug developed by Janssen Pharmaceuticals, a division of Johnson and Johnson, and Bayer AG.
TheProductLawyers.com reports on the plaintiffs suing the makers of Xarelto, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, and their reaction to Xarelto commercials.
TheProductLawyers.com reports on case management orders issued by Judge Eldon Fallon in the MDL No. 2592 against Xarelto.
TheProductLawyers.com reports on recent research which may show a potential link between the use of Xarelto and serious health risks which have been claimed by plaintiffs in the multidistrict litigation (MDL) 2592 against the manufacturers of Xarelto—Bayer AG and Janssen Pharmaceuticals.
Representing nearly 3,000 individual lawsuits, the MDL was consolidated late last year by the U.S. Judicial Panel on Multidistrict Litigation (JPML).